XORTX Therapeutics (XRTX) Shares Outstanding (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Shares Outstanding (Entity) came in at $13.9 million in Q1 2026, up 86.3% YoY from $7.5 million in Q1 2025, and up 47.05% on a QoQ basis from $9.5 million in Q4 2025.
XORTX Therapeutics (XRTX) Shares Outstanding (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Shares Outstanding (Entity) data on file, last reported at $13.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 86.3% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (up 86.3% YoY) and the FY2025 annual result came in at $9.5 million, up 64.48% from the prior year.
- Shares Outstanding (Entity) improved to $13.9 million in Q1 2026, from $9.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $13.9 million in Q1 2026 to a low of $2.9 million in Q1 2022.
- A 5-year average of $5.8 million and a median of $4.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) grew 25.91% — and 2026, when it surged 86.3%.
- Tracing XRTX's Shares Outstanding (Entity) over 5 years: stood at $3.0 million in 2022, then surged by 33.91% to $4.0 million in 2023, then soared by 45.25% to $5.8 million in 2024, then surged by 64.48% to $9.5 million in 2025, then jumped by 47.05% to $13.9 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $13.9 million (Q1 2026), $9.5 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 946,927.00 |
| Sep 30, 2025 | 971,299.00 |
| Jun 30, 2025 | 757,649.00 |
| Mar 31, 2025 | 747,420.00 |
| Dec 31, 2024 | 575,703.00 |
| Sep 30, 2024 | 580,713.00 |
| Jun 30, 2024 | 580,713.00 |
| Mar 31, 2024 | 485,854.00 |
| Dec 31, 2023 | 396,347.00 |
| Sep 30, 2023 | 399,770.00 |
| Jun 30, 2023 | 399,767.00 |
| Mar 31, 2023 | 385,885.00 |
| Dec 31, 2022 | 295,980.00 |
| Sep 30, 2022 | 288,657.00 |
| Jun 30, 2022 | 288,657.00 |
| Mar 31, 2022 | 288,657.00 |
| Dec 31, 2021 | 218,834.00 |
| Sep 30, 2021 | 208,912.00 |
| Jun 30, 2021 | 208,358.00 |